Clinical Trials Using PI3K-gamma Inhibitor IPI-549
Clinical trials are research studies that involve people. The clinical trials on this list are studying PI3K-gamma Inhibitor IPI-549. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)
MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC).
Location: 6 locations
Study to Evaluate the Efficacy / Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
Location: 3 locations
IPI-549 for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
This phase II trial studies how well IPI-549 works in treating patients with head and neck squamous cell carcinoma that has spread to nearby tissue or lymph nodes (locally advanced). IPI-549 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: University of California San Diego, San Diego, California
A Study to Evaluate Safety / Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
This is a Phase 1 / 1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or without IPI-549 in participants with advanced metastatic triple-negative breast cancer (TNBC) or ovarian cancer, and etrumadenant in combination with nanoparticle albumin-bound-paclitaxel (NP) in participants with advanced metastatic TNBC.
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California